Austell Pharmaceuticals ( Pty) Limited Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Austell Pharmaceuticals ( Pty) Limited Pharmaceutical Import Records from India — 2 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Austell Pharmaceuticals ( Pty) Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $1.4M Trade | TransData Nexus

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Enalapril	Cardiovascular	$930.7K	23	0.4%	8
2	Teicoplanin	Advanced Antibiotics	$445.1K	9	2.4%	1

Austell Pharmaceuticals ( Pty) Limited imports 2 pharmaceutical products across 2 categories into South Africa totaling $1.4M. The company is the #1 buyer for 1 product: Teicoplanin.

Austell Pharmaceuticals ( Pty) Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Austell Pharmaceuticals (Pty) Limited, established in 2005, is a privately held pharmaceutical company headquartered in Johannesburg, South Africa. The company specializes in the manufacturing and distribution of both premium and generic medicines, adhering to international standards of safety and efficacy. Austell's product portfolio includes over 150 over-the-counter and prescription medications, such as Amuco 600, Piascledine, Prospan, Reuterina, and Sinupret, which are widely prescribed in the South African market. (austell.co.za)

The company operates with a patient-centric approach, emphasizing ethical practices and community engagement. Austell sponsors medical students annually, donates medications to communities in need, and is involved in diverse community projects. In July 2023, Austell expanded into the medical aesthetics market with the launch of Xeomin in South Africa, marking a significant milestone in its growth trajectory. (austell.co.za)

2Distribution Network

Austell Pharmaceuticals maintains a robust distribution network across South Africa, ensuring widespread availability of its products. The company's primary warehouse is located at 1 Sherborne Road, Parktown, Johannesburg, with additional facilities in Cape Town and Durban. This strategic positioning facilitates efficient logistics and timely delivery to hospitals, pharmacies, and clinics nationwide.

While specific details about Austell's international distribution are limited, the company's expansion into the medical aesthetics market in July 2023 suggests a growing interest in broader regional markets. This move indicates potential plans to extend its distribution network beyond South Africa, leveraging its established infrastructure and market presence. (austell.co.za)

3Industry Role

Austell Pharmaceuticals operates as a pharmaceutical manufacturer and distributor within South Africa's healthcare sector. The company is not a wholesaler, parallel importer, hospital supplier, or logistics intermediary; rather, it focuses on the production and direct distribution of its own branded products. This model allows Austell to maintain control over product quality, branding, and market positioning. (austell.co.za)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Austell Pharmaceuticals ( Pty) Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Austell Pharmaceuticals imports finished pharmaceutical formulations from India, with a total import value of $1.4 million USD across 32 shipments. The company's portfolio is highly concentrated, with the top five products accounting for 100% of imports. Notably, Teicoplanin and Enalapril are the primary imports, with Teicoplanin leading at $445K (2.4% share) and Enalapril at $931K (0.4% share). (austell.co.za)

This sourcing strategy indicates a strategic choice to focus on high-demand, specialized products. The significant import value of Teicoplanin suggests a strong and stable relationship with Indian suppliers, particularly in the area of advanced antibiotics. However, the heavy reliance on a limited number of products may expose Austell to supply chain risks if there are disruptions in the Indian market.

2Supply Chain Resilience

Austell Pharmaceuticals' supply chain resilience is closely tied to its sourcing strategy from India. The company's focus on finished pharmaceutical formulations, such as Teicoplanin and Enalapril, indicates a reliance on suppliers who can meet stringent quality standards. While specific details about backup suppliers and formulation diversity are not publicly available, the concentration on a few key products suggests that Austell may have established strong partnerships with select Indian manufacturers.

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

In South Africa, the South African Health Products Regulatory Authority (SAHPRA) is responsible for regulating the safety, efficacy, and quality of health products, including pharmaceuticals. SAHPRA operates under the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), which provides the legislative framework for the regulation of medicines and related substances in the country.

For Indian pharmaceutical companies seeking to export to South Africa, obtaining marketing authorization from SAHPRA is mandatory. This process involves submitting comprehensive documentation, including clinical trial data, manufacturing details, and quality control measures, to demonstrate compliance with South African standards.

2Import Licensing & GMP

Import licensing in South Africa is governed by SAHPRA, which requires all imported pharmaceutical products to be registered and authorized before they can be marketed. Indian exporters must ensure that their products meet Good Manufacturing Practice (GMP) standards recognized by SAHPRA. SAHPRA accepts GMP certifications from reputable authorities, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Additionally, Indian exporters must obtain wholesale distribution authorization from SAHPRA to distribute their products within South Africa. This authorization ensures that the distributor complies with all regulatory requirements and maintains the integrity of the supply chain.

Austell Pharmaceuticals ( Pty) Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Austell Pharmaceuticals' focus on cardiovascular and advanced antibiotics therapeutic categories aligns with prevalent health concerns in South Africa, such as hypertension and infectious diseases. The importation of Teicoplanin and Enalapril addresses critical treatment needs in these areas, reflecting a strategic response to market demand.

The company's expansion into the medical aesthetics market with the launch of Xeomin in July 2023 indicates a diversification strategy aimed at tapping into emerging market segments and meeting evolving consumer preferences. This move suggests a forward-thinking approach to product development and market positioning. (austell.co.za)

2Sourcing Profile

Austell Pharmaceuticals' sourcing strategy emphasizes high-quality, finished pharmaceutical formulations from India, focusing on products with established efficacy and safety profiles. This approach ensures that the company can offer reliable and effective treatments to the South African market.

India's well-established pharmaceutical manufacturing sector, recognized for its adherence to international GMP standards, makes it a preferred sourcing destination for Austell. The company's selective importation of specific products indicates a strategic approach to procurement, aiming to meet targeted therapeutic needs while maintaining quality and cost-effectiveness.

Market Positioning

Seller's Guide — How to Become a Supplier to Austell Pharmaceuticals ( Pty) Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Austell Pharmaceuticals, particularly in the cardiovascular and advanced antibiotics therapeutic categories. Austell's focus on high-quality, finished pharmaceutical formulations presents an avenue for Indian exporters to introduce products that meet stringent quality standards.

However, the heavy concentration on a limited number

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Austell Pharmaceuticals ( Pty) Limited

What products does Austell Pharmaceuticals ( Pty) Limited import from India?

Austell Pharmaceuticals ( Pty) Limited imports 2 pharmaceutical products across 2 categories. Top imports: Enalapril ($930.7K), Teicoplanin ($445.1K).

What is Austell Pharmaceuticals ( Pty) Limited's total pharmaceutical import value?

Austell Pharmaceuticals ( Pty) Limited's total pharmaceutical import value from India is $1.4M, based on 32 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Austell Pharmaceuticals ( Pty) Limited focus on?

Austell Pharmaceuticals ( Pty) Limited imports across 2 categories. The largest: Cardiovascular (67.6%), Advanced Antibiotics (32.4%).

Get Full Austell Pharmaceuticals ( Pty) Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Austell Pharmaceuticals ( Pty) Limited

Austell Pharmaceuticals ( Pty) Limited — Import Portfolio & Supplier Network

What Products Does Austell Pharmaceuticals ( Pty) Limited Import?

Top Products by Import Value

Austell Pharmaceuticals ( Pty) Limited Therapeutic Categories — 2 Specializations